The second half of April 2026 shows three clear signals. Oncology programs are moving into direct competitive tests, PAH and obesity remain active cardiometabolic frontiers, and autoimmune cell therapy is moving from early excitement into industrial validation.
The strongest signals include BMS moving CD19 CAR T into Phase 3 systemic sclerosis, Roche testing NXT007 against its own Hemlibra franchise, Janssen running an IL 23 head to head trial in Crohn’s disease, and HELP Therapeutics taking iPSC derived cardiomyocytes into advanced heart failure.
Across this edition, the larger pattern is clear. Sponsors are not only testing whether programs can work. They are testing where conviction, differentiation and commercial positioning can hold.